Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics
Deal validates Jeito’s unique investment model of selecting high-quality assets developed by world-leading teams in therapeutic areas with high unmet needParis, France, November 29th 2022 - Jeito Capital ("Jeito"), the largest fully independent international private...
Find all our press releases
Jeito Capital co-leads $76 million Series A financing for CDR-Life its 10th investment since its launch
Paris, France, April 13, 2022 - Jeito Capital ("Jeito"), a leading independent Private Equity firm...
Jeito Capital co-leads EUR 80 million euro Series B financing in European oncology company, Precirix
Paris, France, March 2022, 16th – Jeito Capital (“Jeito”), a leading independent private equity...
Paris, France, 22 February 2022 – Jeito Capital (“Jeito”), a leading independent private equity...
Jeito Capital announces the appointments of Dr Andreas Wallnoefer as Partner Investor and Isabelle Meyrier as Head of Legal
Paris, France, February 17, 2022 - Jeito Capital ("Jeito"), a leading independent private equity...
Jeito Capital selected European clinical stage biotech NMD Pharma, based in Denmark, as its 7th...
Quell Therapeutics is the world leader in developing engineered T-regulatory (Tregs) cell...
Face to face
All day long
For more than 25 years, BIO-Europe is one of the most influential life sciences trade shows thanks to the synergies it creates in order to bring out medical innovations.
During this event, Sabine Dandigiuan, Managing Partner of Jeito Capital, will participate in the “Talent: finding it, developing it, keeping it” panel.
All day long
HealthTech Innovation Days 2021
Jeito Capital will be Silver Sponsor at HealthTech Innovation Days 2021.
Attend to Rafaèle Tordjman, MD PhD, Keynote on October, 5 at 6.30 PM CET